Adjuvant therapy in colon cancer

Lucia Lombardi, Vittorio Gebbia, Nicola Silvestris, Antonio Testa, Giuseppe Colucci, Evaristo Maiello

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Colon cancer is the second leading cause of cancer death worldwide. Approximately three quarters of patients are diagnosed with disease limited to the bowel wall or surrounding lymph nodes. Over the past decade, significant progress has been made in the treatment of localized colon cancer. The use of adjuvant chemotherapy has improved prognosis in stage III disease, but much work remains to be done in optimizing adjuvant treatment. The FOLFOX4 regimen is now considered standard treatment for stage III disease. Combinations of irinotecan and 5-fluorouracil (5-FU) have not proven to be more effective than 5-FU/folinic acid. In stage II, the value of post-operative treatment remains controversial, but the identification of histopathological and molecular prognostic factors would allow selection of patients who can benefit from adjuvanttreatment. The inclusion of molecular targeted agents in combination regimens with cytotoxins, which have already proven effective in advanced disease, is the main field of development in the most recent protocols of adjuvant therapy.

Original languageEnglish
Pages (from-to)50-56
Number of pages7
JournalOncology
Volume77
Issue numberSUPPL. 1
DOIs
Publication statusPublished - Feb 2010

Fingerprint

Colonic Neoplasms
irinotecan
Fluorouracil
Therapeutics
Leucovorin
Cytotoxins
Adjuvant Chemotherapy
Patient Selection
Cause of Death
Lymph Nodes
Neoplasms

Keywords

  • Adjuvant chemotherapy
  • Colon cancer
  • Targeted therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Lombardi, L., Gebbia, V., Silvestris, N., Testa, A., Colucci, G., & Maiello, E. (2010). Adjuvant therapy in colon cancer. Oncology, 77(SUPPL. 1), 50-56. https://doi.org/10.1159/000258496

Adjuvant therapy in colon cancer. / Lombardi, Lucia; Gebbia, Vittorio; Silvestris, Nicola; Testa, Antonio; Colucci, Giuseppe; Maiello, Evaristo.

In: Oncology, Vol. 77, No. SUPPL. 1, 02.2010, p. 50-56.

Research output: Contribution to journalArticle

Lombardi, L, Gebbia, V, Silvestris, N, Testa, A, Colucci, G & Maiello, E 2010, 'Adjuvant therapy in colon cancer', Oncology, vol. 77, no. SUPPL. 1, pp. 50-56. https://doi.org/10.1159/000258496
Lombardi L, Gebbia V, Silvestris N, Testa A, Colucci G, Maiello E. Adjuvant therapy in colon cancer. Oncology. 2010 Feb;77(SUPPL. 1):50-56. https://doi.org/10.1159/000258496
Lombardi, Lucia ; Gebbia, Vittorio ; Silvestris, Nicola ; Testa, Antonio ; Colucci, Giuseppe ; Maiello, Evaristo. / Adjuvant therapy in colon cancer. In: Oncology. 2010 ; Vol. 77, No. SUPPL. 1. pp. 50-56.
@article{373e93e437d947a6bdb9d723e6f1eb24,
title = "Adjuvant therapy in colon cancer",
abstract = "Colon cancer is the second leading cause of cancer death worldwide. Approximately three quarters of patients are diagnosed with disease limited to the bowel wall or surrounding lymph nodes. Over the past decade, significant progress has been made in the treatment of localized colon cancer. The use of adjuvant chemotherapy has improved prognosis in stage III disease, but much work remains to be done in optimizing adjuvant treatment. The FOLFOX4 regimen is now considered standard treatment for stage III disease. Combinations of irinotecan and 5-fluorouracil (5-FU) have not proven to be more effective than 5-FU/folinic acid. In stage II, the value of post-operative treatment remains controversial, but the identification of histopathological and molecular prognostic factors would allow selection of patients who can benefit from adjuvanttreatment. The inclusion of molecular targeted agents in combination regimens with cytotoxins, which have already proven effective in advanced disease, is the main field of development in the most recent protocols of adjuvant therapy.",
keywords = "Adjuvant chemotherapy, Colon cancer, Targeted therapy",
author = "Lucia Lombardi and Vittorio Gebbia and Nicola Silvestris and Antonio Testa and Giuseppe Colucci and Evaristo Maiello",
year = "2010",
month = "2",
doi = "10.1159/000258496",
language = "English",
volume = "77",
pages = "50--56",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Adjuvant therapy in colon cancer

AU - Lombardi, Lucia

AU - Gebbia, Vittorio

AU - Silvestris, Nicola

AU - Testa, Antonio

AU - Colucci, Giuseppe

AU - Maiello, Evaristo

PY - 2010/2

Y1 - 2010/2

N2 - Colon cancer is the second leading cause of cancer death worldwide. Approximately three quarters of patients are diagnosed with disease limited to the bowel wall or surrounding lymph nodes. Over the past decade, significant progress has been made in the treatment of localized colon cancer. The use of adjuvant chemotherapy has improved prognosis in stage III disease, but much work remains to be done in optimizing adjuvant treatment. The FOLFOX4 regimen is now considered standard treatment for stage III disease. Combinations of irinotecan and 5-fluorouracil (5-FU) have not proven to be more effective than 5-FU/folinic acid. In stage II, the value of post-operative treatment remains controversial, but the identification of histopathological and molecular prognostic factors would allow selection of patients who can benefit from adjuvanttreatment. The inclusion of molecular targeted agents in combination regimens with cytotoxins, which have already proven effective in advanced disease, is the main field of development in the most recent protocols of adjuvant therapy.

AB - Colon cancer is the second leading cause of cancer death worldwide. Approximately three quarters of patients are diagnosed with disease limited to the bowel wall or surrounding lymph nodes. Over the past decade, significant progress has been made in the treatment of localized colon cancer. The use of adjuvant chemotherapy has improved prognosis in stage III disease, but much work remains to be done in optimizing adjuvant treatment. The FOLFOX4 regimen is now considered standard treatment for stage III disease. Combinations of irinotecan and 5-fluorouracil (5-FU) have not proven to be more effective than 5-FU/folinic acid. In stage II, the value of post-operative treatment remains controversial, but the identification of histopathological and molecular prognostic factors would allow selection of patients who can benefit from adjuvanttreatment. The inclusion of molecular targeted agents in combination regimens with cytotoxins, which have already proven effective in advanced disease, is the main field of development in the most recent protocols of adjuvant therapy.

KW - Adjuvant chemotherapy

KW - Colon cancer

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=77949901120&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949901120&partnerID=8YFLogxK

U2 - 10.1159/000258496

DO - 10.1159/000258496

M3 - Article

VL - 77

SP - 50

EP - 56

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - SUPPL. 1

ER -